Beta
Ketoconazole and other strong CYP3A4 inhibitors
medication Under reviewKetoconazole and several other drugs, including itraconazole, clarithromycin, and ritonavir, are classified as strong inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme. CYP3A4 is one of the major drug‑metabolizing enzymes in the liver and intestine, responsible for the clearance of a large proportion of prescription medications. When a strong CYP3A4 inhibitor is coadministered with a CYP3A4 substrate, it can markedly increase the substrate’s blood levels by reducing its metabolic clearance. Ketoconazole, originally developed as an antifungal agent, inhibits CYP3A4 by binding to the enzyme’s heme iron through its azole moiety, blocking access of other drugs to the active site. Other strong CYP3A4 inhibitors such as itraconazole and ritonavir act through similar high‑affinity binding, sometimes with additional effects on drug transporters like P‑glycoprotein and organic anion transporting polypeptides. In healthy volunteers, these agents are primarily used as pharmacologic tools in drug–drug interaction studies to characterize the sensitivity of new drugs to CYP3A4 inhibition, rather than to obtain direct health benefits.
Research summary
In healthy human subjects, strong CYP3A4 inhibitors such as ketoconazole have been used extensively to quantify how much they increase exposure to various CYP3A4 substrate drugs. Controlled pharmacokinetic studies consistently show large increases in substrate area under the curve (AUC) and peak concentrations for many sensitive substrates, although the magnitude depends on the specific substrate and on whether transporters are also involved. These studies have also been used to compare ketoconazole with alternative strong inhibitors like itraconazole, clarithromycin, and ritonavir, which can differ in their transporter inhibition profiles and overall interaction patterns. From a safety standpoint, single‑dose or short‑course use of ketoconazole and related inhibitors in healthy volunteers is generally well tolerated, with adverse events usually limited to mild gastrointestinal or neurologic symptoms. However, longer‑term therapeutic use of oral ketoconazole has been restricted due to risks of idiosyncratic hepatotoxicity and adrenal suppression, leading regulators to discourage its use in dedicated interaction studies and encourage alternative strong CYP3A4 inhibitors. Overall, the research in healthy humans supports a strong and predictable inhibitory effect on CYP3A4‑mediated drug clearance, but does not support any intrinsic health benefit for otherwise healthy individuals.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!